Surya Mohapatra - Xylem Independent Director
| XYL Stock | USD 127.01 0.26 0.21% |
Director
Dr. Surya N. Mohapatra, Ph.D., is an Independent Director of the Company. He served as Chief Executive Officer and Chairman of Quest Diagnostics Incorporated, a leading provider of diagnostic information services, from 2004 until his retirement in 2012. Dr. Mohapatra joined Quest Diagnostics as Senior Vice President and Chief Operating Officer in 1999. Prior to joining Quest Diagnostics, Dr. Mohapatra was Senior Vice President and a member of the executive committee of Picker International, a worldwide leader in advanced medical imaging technologies, where he served in various executive positions during his 18year tenure. Dr. Mohapatra serves as a Director on the Board of Leidos, a science and technology company, is a Director on the board of Malaria No More and is a trustee of The Rockefeller University. He is also an ExecutiveinResidence at Columbia Business School. since 2011.
| Age | 71 |
| Tenure | 13 years |
| Professional Marks | Ph.D |
| Address | 300 Water Street SE, Washington, DC, United States, 20003 |
| Phone | 202 869 9150 |
| Web | https://www.xylem.com |
Xylem Management Efficiency
The company has Return on Asset of 0.0443 % which means that on every $100 spent on assets, it made $0.0443 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0808 %, implying that it generated $0.0808 on every 100 dollars invested. Xylem's management efficiency ratios could be used to measure how well Xylem manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Xylem's Return On Tangible Assets are quite stable compared to the past year. Return On Assets is expected to rise to 0.07 this year, although the value of Return On Capital Employed will most likely fall to 0.04. At this time, Xylem's Debt To Assets are quite stable compared to the past year. Fixed Asset Turnover is expected to rise to 8.42 this year, although the value of Other Current Assets will most likely fall to about 159.6 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Billie Williamson | Pentair PLC | 68 | |
| Arthur Golden | Emerson Electric | 74 | |
| Mark Smith | Smith AO | 59 | |
| Daniel Brutto | Illinois Tool Works | 64 | |
| Nicholas Fanandakis | ITT Inc | 64 | |
| Rebecca McDonald | ITT Inc | 67 | |
| James Turley | Emerson Electric | 65 | |
| Gregory Page | Eaton PLC | 69 | |
| Eric Spiegel | Dover | 63 | |
| Idelle Wolf | Smith AO | 68 | |
| Silvio Napoli | Eaton PLC | 56 | |
| Pamela Strobel | Illinois Tool Works | 68 | |
| Stephen Wagner | Dover | 74 | |
| James Wainscott | Parker Hannifin | 63 | |
| Matthew Levatich | Emerson Electric | 55 | |
| Donald DeFosset | ITT Inc | 72 | |
| Clemens Boersig | Emerson Electric | 72 | |
| Ernest Mrozek | IDEX Corporation | 67 | |
| Ilham Kadri | Smith AO | 52 | |
| William Easter | Emerson Electric | 71 | |
| Ake Svensson | Parker Hannifin | 68 | |
Management Performance
| Return On Equity | 0.0808 | |||
| Return On Asset | 0.0443 |
Xylem Inc Leadership Team
Elected by the shareholders, the Xylem's board of directors comprises two types of representatives: Xylem inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Xylem. The board's role is to monitor Xylem's management team and ensure that shareholders' interests are well served. Xylem's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Xylem's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Colin Sabol, Senior Vice President and President, Measurement & Control Solutions | ||
| Thomas Pettit, Senior Officer | ||
| Matthew Latino, Director - Investor Relations | ||
| Markos Tambakeras, Non-Executive Independent Chairman of the Board | ||
| Uday Yadav, Independent Director | ||
| Victoria Harker, Independent Director | ||
| Surya Mohapatra, Independent Director | ||
| Mark Morelli, Independent Director | ||
| William Grogan, Senior CFO | ||
| Steven Loranger, Independent Director | ||
| Curtis Crawford, Independent Director | ||
| Lila Tretikov, Independent Director | ||
| Jerome Peribere, Independent Director | ||
| Jorge Gomez, Independent Director | ||
| Robert Friel, Independent Chairman of the Board | ||
| Shuping Lu, President Asia | ||
| Kairus Tarapore, Chief Human Resource Officer, Senior Vice President | ||
| David Flinton, Senior VP and Chief Innovation, Technology & Products Officer, Acting President - Water Infrastructure and Europe Commercial Team | ||
| GeriMichelle McShane, Chief Accounting Officer, Vice President Controller | ||
| Matthew Pine, Senior Vice President and Presidentident - Applied Water Systems and Americas Commercial Team | ||
| Pak Leung, Senior Vice President and President - Emerging Markets | ||
| Claudia Toussaint, Chief Human Resource and Sustainability Officer, Senior Vice President, General Counsel, Company Secretary | ||
| JD Esq, Chief VP | ||
| Hayati Yarkadas, Senior Vice President and Presidentident - Water Infrastructure and Europe Commercial Team | ||
| Franz Cerwinka, Senior Vice President and President Emerging Markets | ||
| E Rajkowski, Chief Financial Officer, Senior Vice President | ||
| Sandra Rowland, Chief Financial Officer, Senior Vice President | ||
| John Kehoe, VP Officer | ||
| Jeanne BeliveauDunn, Independent Director | ||
| Patrick Decker, President, Chief Executive Officer, Director | ||
| Sten Jakobsson, Independent Director | ||
| Albert Cho, Senior Officer | ||
| Andrea Berg, Vice Relations | ||
| Dorothy Capers, Senior Vice President General Counsel |
Xylem Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Xylem a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0808 | |||
| Return On Asset | 0.0443 | |||
| Profit Margin | 0.1 % | |||
| Operating Margin | 0.14 % | |||
| Current Valuation | 31.91 B | |||
| Shares Outstanding | 242.94 M | |||
| Shares Owned By Insiders | 0.64 % | |||
| Shares Owned By Institutions | 93.80 % | |||
| Number Of Shares Shorted | 2.3 M | |||
| Price To Earning | 64.49 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xylem Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Industrial Machinery & Supplies & Components space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xylem. If investors know Xylem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xylem listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.413 | Dividend Share 1.41 | Earnings Share 3.49 | Revenue Per Share 34.788 | Quarterly Revenue Growth 0.013 |
The market value of Xylem Inc is measured differently than its book value, which is the value of Xylem that is recorded on the company's balance sheet. Investors also form their own opinion of Xylem's value that differs from its market value or its book value, called intrinsic value, which is Xylem's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xylem's market value can be influenced by many factors that don't directly affect Xylem's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xylem's value and its price as these two are different measures arrived at by different means. Investors typically determine if Xylem is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xylem's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.